Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

Table 2 Univariate and multivariable Cox regression analysis of predicting progression-free survival in patients with microsatellite-stable colorectal cancer treated with immune checkpoint inhibitors

Variable	Univariable			Multivariable
	HR	95%CI	P value	HR	95%CI	P value
Gender (female vs male)	1.52	0.69-3.31	0.30
Age (> 60 vs ≤ 60 years)	1.25	0.56-2.81	0.59
BMI
< 18.5	Reference
18.5-24	2.70	0.36-20.43	0.34
> 24	3.49	0.41-29.75	0.25
Differentiation (moderately & well & chronic inflammation after neoadjuvant therapy vs poorly)	0.41	0.12-1.37	0.15
Pathological type
Chronic inflammation after neoadjuvant therapy	Reference
Adenocarcinoma	1.58	0.21-11.88	0.66
Special histologic type adenocarcinoma	0.63	0.06-7.00	0.71
Mixed	0.66	0.04-10.75	0.77
Tumor location
Left colon	Reference
Right colon	0.72	0.31-1.65	0.44
Mixed	4.58	0.54-38.86	0.16
Tumor size (< 4 cm vs ≥ 4 cm)	0.45	0.17-1.19	0.11
AJCC stage (III& IV vs I& II)	2.04	0.59-7.01	0.26
HRD (yes vs no)	0.31	0.09-1.03	0.06	0.31	0.09-1.03	0.05a

^aP ≤ 0.05.

HRD: Homologous recombination deficiency; BMI: Body mass index.